Related Experiment Video

Updated: May 17, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data

Parag H Joshi1, Rita R Kalyani, Roger S Blumenthal

  • 1Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. pjoshi9@jhmi.edu

The American Journal of Cardiology
|October 16, 2012
PubMed

Insights

Preventing cardiovascular events in type 2 diabetes requires managing multiple risk factors. This review examines glucose-lowering drugs, emphasizing cardiovascular outcomes and multifactorial interventions for macrovascular complication prevention.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (DM) significantly increases macrovascular complication risk due to atherosclerosis and thrombosis.
  • Effective management involves addressing hyperglycemia, dyslipidemia, hypertension, inflammation, and thrombotic tendencies.

Purpose of the Study:

  • To review cardiovascular benefits and harms of noninsulin, glucose-lowering agents in type 2 DM.
  • To provide recommendations for preventing cardiovascular events based on current evidence.

Main Methods:

  • Literature review focusing on cardiovascular outcomes of glucose-lowering therapies.
  • Analysis of data from clinical trials, including ongoing phase 3-4 trials.

Main Results:

  • Traditional glucose-lowering agents often lack long-term cardiovascular outcome data.
  • Intensive hemoglobin A1c reduction may pose risks.
  • Incretin-based therapies are under extensive investigation for cardiovascular effects.

Conclusions:

  • Multifactorial risk intervention is crucial for preventing macrovascular complications in type 2 DM.
  • Therapeutic strategies should integrate lifestyle changes, antihyperglycemics, antihypertensives, statins, and aspirin.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...